Cervical cancer vaccines: progress and prospects.
Cervical cancer remains a leading cause of cancer-related mortality in women, particularly in developing countries. The causal association between genital human papillomavirus (HPV) infection and cervical cancer has been firmly established and the oncogenic potential of certain HPV types has been clearly demonstrated. In recognition of the causal association of cervical cancer with this sexually transmitted viral infection, substantial interest has arisen to develop effective prophylactic and therapeutic vaccines. Prophylactic strategies currently under investigation focus on the induction of effective humoral and cellular immune responses that are potentially protective against subsequent HPV infection. Papillomavirus-like particles have been synthesized to induce neutralizing antibody responses, and impressive immunoprophylactic effects have been demonstrated in both animals and humans. For the treatment of existing HPV infection, techniques to augment cellular immunity by enhancing viral antigen recognition are under investigation. Vaccines targeting the oncogenic proteins E6 and E7 of HPV-16 and -18 are the focus of current clinical trials for cervical cancer patients. It is hoped that the development of successful HPV-specific vaccines will diminish the costs of existing cervical cancer screening programs and reduce the morbidity and mortality associated with the treatment of cervical neoplasias.
Steller
Michael A
MA
Program in Women's Oncology, Women and Infants' Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brown University School of Medicine, Rhode Island, Providence, USA. michael_steller@cchcs.org
D000956:Antigens, Viral / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000517:prevention & control; D014412:Tumor Virus Infections / Q000517:prevention & control; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy* / Q000821:virology; D014764:Viral Proteins / Q000276:immunology
D000956:Antigens, Viral; D019496:Cancer Vaccines; D014764:Viral Proteins